Indeed, according to clinical practice guidelines, neoadjuvant chemotherapy represents the standard of care for HER2+ and triple-negative BC nowadays [40]; consequently, these two latter subtypes are less represented among our patients (12.12% and 4.04%, respectively). This evidence concerns the gene ERBB2 and breast cancer.